WHEN TO TREAT? HOW TO TREAT? Our diagnostics help decide.

At DDTD, we embrace the ideal of eliminating diseases that do not belong to the 21st century. The first step towards eliminating a disease is the ability to detect it. Mapping diseases is critical for the World Health Organization (WHO) and its affiliates to initiate mass drug administration programs, allocate resources, monitor progress, and eventually verify elimination. 


Loiasis Antibody Test


DDTD has developed a rapid diagnostic test designed for the high-resolution mapping of L. loa. The Loa Antibody Rapid Test is a Research Use Only (RUO) device. It is intended for epidemiology purposes and as a population surveillance tool. Help support RDTs to map Loasis.   More information →

River Blindness

River Blindness.jpg

New RDTs to detect live O. volvulus infections are acutely needed. Currently, onchocerciasis is diagnosed by collecting small amounts of skin biopsies with a blade, dipping them in saline, and examining by microscopy if O. volvulus microfilariae have been released into the saline. More information →


Lymphatic Filariasis

Lymphatic Filariasis 2.jpg

The only proven field-deployable test for lymphatic filariasis currently is the immunochromatography testcard (ICT), that has been used for 2 decades to detect active infections. However, the ICT card is not suited for surveillance activities, as it detects the disease only 18 months after a person has been infected and lacks sensitivity in post-mass drug administration settings (due to low parasite burden). Experts agree that what is required for surveillance is a RDT indicative of early exposure to W. bancrofti infective larvae.  More information →

Other Efforts


We seek to reduce health inequity within local communities by providing a portfolio of low-cost rapid diagnostic tests (RDTs) developed specifically for homeless individuals and people living in precarious conditions. Our initial focus will be hepatitis A (HAV), a highly contagious disease which struck the homeless and illicit drug user populations in San Diego and surrounding areas over the last year. HAV epidemics are also active in other parts of the nation, including Michigan, Kentucky, Utah, and Washington State.                                              More information →